100245-03-2

Basic information

• Product Name: Benzamide, 2-hydroxy-N,N,5-trimethyl-
• CAS NO: 100245-03-2
• Molecular Formula: C10H13NO2
• Molecular Weight: 179.219
• Mol File: 100245-03-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzamide, 2-hydroxy-N,N,5-trimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 2-hydroxy-N,N,5-trimethyl-(100245-03-2)
• EPA Substance Registry System: Benzamide, 2-hydroxy-N,N,5-trimethyl-(100245-03-2)

Safety Data

• Hazardous Substances Data: 100245-03-2(Hazardous Substances Data)

Upstream product

• 6935-65-5 3,N,N-trimethylbenzamide 
• 1711-06-4 3-Methylbenzoyl chloride 

Downstream Products

• 70978-09-5 3-Amino-2-hydroxy-5-methyl-N,N-dimethyl-benzamid 
• 70978-13-1 1-benzyl-1H-tetrazole-5-carboxylic acid 3-dimethylcarbamoyl-2-hydroxy-5-methyl-anilide 
• 70977-54-7 1⁽²⁾H-tetrazole-5-carboxylic acid 3-dimethylcarbamoyl-2-hydroxy-5-methyl-anilide 
• 70978-44-8 N,N-dimethyl-2-hydroxy-5-methyl-3-nitrobenzamide 

Relevant articles and documents

Rhoda-Electrocatalyzed Bimetallic C?H Oxygenation by Weak O-Coordination

Rhodium-electrocatalyzed arene C?H oxygenation by weakly O-coordinating amides and ketones have been established by bimetallic electrocatalysis. Likewise, diverse dihydrooxazinones were selectively accessed by the judicious choice of current, enabling twofold C?H functionalization. Detailed mechanistic studies by experiment, mass spectroscopy and cyclovoltammetric analysis provided support for an unprecedented electrooxidation-induced C?H activation by a bimetallic rhodium catalysis manifold.

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.